Article

Key clinical point: Minimal important change (MIC) of the Psoriatic Arthritis Disease Activity Score (PASDAS) could help physicians understand patients' perspectives of disease activity and provide an additional tool for the treatment of psoriatic arthritis (PsA).

Major finding: The overall MIC of the PASDAS was 0.67 (95% CI 0.55-0.79) and results for improvement and deterioration were 0.65 (95% CI 0.46-0.83) and 0.71 (95% CI 0.49-0.93), respectively.

Study details: Findings are from a retrospective cohort study that evaluated routine practice data of 408 patients with PsA.

Disclosures: This work was supported by the Regional Junior Researcher Grant from the Sint Maartenskliniek, Nijmegen, and the Radboudumc, Nijmegen, the Netherlands. The authors declared no conflicts of interest.

Source: Mulder MLM et al. Rheumatology (Oxford). 2022 (Jan 13). Doi: 10.1093/rheumatology/keac025.

Key clinical point: Minimal important change (MIC) of the Psoriatic Arthritis Disease Activity Score (PASDAS) could help physicians understand patients' perspectives of disease activity and provide an additional tool for the treatment of psoriatic arthritis (PsA).

Major finding: The overall MIC of the PASDAS was 0.67 (95% CI 0.55-0.79) and results for improvement and deterioration were 0.65 (95% CI 0.46-0.83) and 0.71 (95% CI 0.49-0.93), respectively.

Study details: Findings are from a retrospective cohort study that evaluated routine practice data of 408 patients with PsA.

Disclosures: This work was supported by the Regional Junior Researcher Grant from the Sint Maartenskliniek, Nijmegen, and the Radboudumc, Nijmegen, the Netherlands. The authors declared no conflicts of interest.

Source: Mulder MLM et al. Rheumatology (Oxford). 2022 (Jan 13). Doi: 10.1093/rheumatology/keac025.

Key clinical point: Minimal important change (MIC) of the Psoriatic Arthritis Disease Activity Score (PASDAS) could help physicians understand patients' perspectives of disease activity and provide an additional tool for the treatment of psoriatic arthritis (PsA).

Major finding: The overall MIC of the PASDAS was 0.67 (95% CI 0.55-0.79) and results for improvement and deterioration were 0.65 (95% CI 0.46-0.83) and 0.71 (95% CI 0.49-0.93), respectively.

Study details: Findings are from a retrospective cohort study that evaluated routine practice data of 408 patients with PsA.

Disclosures: This work was supported by the Regional Junior Researcher Grant from the Sint Maartenskliniek, Nijmegen, and the Radboudumc, Nijmegen, the Netherlands. The authors declared no conflicts of interest.

Source: Mulder MLM et al. Rheumatology (Oxford). 2022 (Jan 13). Doi: 10.1093/rheumatology/keac025.

Key clinical point: Entheseal power Doppler (PD) signal, entheseal bone erosions, and gray scale (GS) joint synovitis were indicative of severe psoriatic arthritis (PsA) in terms of ultrasound (US)-detected joint bone erosion.

Major finding: At least 1 joint bone erosion was found in 45.2% of patients and was associated with PD signal at enthesis (odds ratio [OR] 1.74; P < .01), entheseal bone erosions (OR 3.17; P = .01), and GS synovitis (OR 2.59; P = .02).

Study details: Findings are from a cross-sectional study including 104 patients with PsA.

Disclosures: This study did not receive any specific funding. E Filippucci and W Grassi declared receiving speaker fees from various sources.

Source: Smerilli G et al. J Rheumatol. 2022 (Feb 1). Doi: 10.3899/jrheum.210974.

Key clinical point: Entheseal power Doppler (PD) signal, entheseal bone erosions, and gray scale (GS) joint synovitis were indicative of severe psoriatic arthritis (PsA) in terms of ultrasound (US)-detected joint bone erosion.

Major finding: At least 1 joint bone erosion was found in 45.2% of patients and was associated with PD signal at enthesis (odds ratio [OR] 1.74; P < .01), entheseal bone erosions (OR 3.17; P = .01), and GS synovitis (OR 2.59; P = .02).

Study details: Findings are from a cross-sectional study including 104 patients with PsA.

Disclosures: This study did not receive any specific funding. E Filippucci and W Grassi declared receiving speaker fees from various sources.

Source: Smerilli G et al. J Rheumatol. 2022 (Feb 1). Doi: 10.3899/jrheum.210974.

Key clinical point: Entheseal power Doppler (PD) signal, entheseal bone erosions, and gray scale (GS) joint synovitis were indicative of severe psoriatic arthritis (PsA) in terms of ultrasound (US)-detected joint bone erosion.

Major finding: At least 1 joint bone erosion was found in 45.2% of patients and was associated with PD signal at enthesis (odds ratio [OR] 1.74; P < .01), entheseal bone erosions (OR 3.17; P = .01), and GS synovitis (OR 2.59; P = .02).

Study details: Findings are from a cross-sectional study including 104 patients with PsA.

Disclosures: This study did not receive any specific funding. E Filippucci and W Grassi declared receiving speaker fees from various sources.

Source: Smerilli G et al. J Rheumatol. 2022 (Feb 1). Doi: 10.3899/jrheum.210974.

Key clinical point: Patients with psoriatic arthritis (PsA) receiving tofacitinib experienced a shorter time to initial clinically meaningful response than those who switched from placebo to tofacitinib.

Major finding: Median time to the initial Health Assessment Questionnaire-Disability Index score response was shorter in patients receiving 5 mg tofacitinib (29-30 days) and 10 mg tofacitinib (53.5 days) than in those switching from placebo to 5 mg tofacitinib (162 days) or 10 mg tofacitinib (112 days; P < .01). The initial Functional Assessment of Chronic Illness Therapy-Fatigue total score response was achieved faster with 5 mg tofacitinib vs. other treatment groups.

Study details: Findings are from a post hoc analysis of 2 phase 3 trials (OPAL BROADEN and OPAL BEYOND) including 816 patients with PsA randomly assigned to 5 mg tofacitinib, 10 mg tofacitinib, 40 mg adalimumab, or placebo switching to 5 or 10 mg tofacitinib at month 3.

Disclosures: This study was funded by Pfizer. The authors declared receiving research grants, consulting fees, and honoraria from Pfizer and other sources. Four authors declared being employees and stockholders of Pfizer.

Source: Gladman DD et al. Arthritis Res Ther. 2022;24:40 (Feb 9). Doi: 10.1186/s13075-022-02721-0.

Key clinical point: Patients with psoriatic arthritis (PsA) receiving tofacitinib experienced a shorter time to initial clinically meaningful response than those who switched from placebo to tofacitinib.

Major finding: Median time to the initial Health Assessment Questionnaire-Disability Index score response was shorter in patients receiving 5 mg tofacitinib (29-30 days) and 10 mg tofacitinib (53.5 days) than in those switching from placebo to 5 mg tofacitinib (162 days) or 10 mg tofacitinib (112 days; P < .01). The initial Functional Assessment of Chronic Illness Therapy-Fatigue total score response was achieved faster with 5 mg tofacitinib vs. other treatment groups.

Study details: Findings are from a post hoc analysis of 2 phase 3 trials (OPAL BROADEN and OPAL BEYOND) including 816 patients with PsA randomly assigned to 5 mg tofacitinib, 10 mg tofacitinib, 40 mg adalimumab, or placebo switching to 5 or 10 mg tofacitinib at month 3.

Disclosures: This study was funded by Pfizer. The authors declared receiving research grants, consulting fees, and honoraria from Pfizer and other sources. Four authors declared being employees and stockholders of Pfizer.

Source: Gladman DD et al. Arthritis Res Ther. 2022;24:40 (Feb 9). Doi: 10.1186/s13075-022-02721-0.

Key clinical point: Patients with psoriatic arthritis (PsA) receiving tofacitinib experienced a shorter time to initial clinically meaningful response than those who switched from placebo to tofacitinib.

Major finding: Median time to the initial Health Assessment Questionnaire-Disability Index score response was shorter in patients receiving 5 mg tofacitinib (29-30 days) and 10 mg tofacitinib (53.5 days) than in those switching from placebo to 5 mg tofacitinib (162 days) or 10 mg tofacitinib (112 days; P < .01). The initial Functional Assessment of Chronic Illness Therapy-Fatigue total score response was achieved faster with 5 mg tofacitinib vs. other treatment groups.

Study details: Findings are from a post hoc analysis of 2 phase 3 trials (OPAL BROADEN and OPAL BEYOND) including 816 patients with PsA randomly assigned to 5 mg tofacitinib, 10 mg tofacitinib, 40 mg adalimumab, or placebo switching to 5 or 10 mg tofacitinib at month 3.

Disclosures: This study was funded by Pfizer. The authors declared receiving research grants, consulting fees, and honoraria from Pfizer and other sources. Four authors declared being employees and stockholders of Pfizer.

Source: Gladman DD et al. Arthritis Res Ther. 2022;24:40 (Feb 9). Doi: 10.1186/s13075-022-02721-0.

Key clinical point: Increased risk for venous thromboembolism (VTE) in patients with psoriatic arthritis (PsA) seemed to be associated with underlying comorbidities and not independently associated with PsA.

Major finding: During follow-up, 1.2% vs. 0.8% patients in the PsA vs. control group were diagnosed with VTE, but this association was not statistically significant after adjusting for demographic factors and comorbidities (adjusted hazard ratio [aHR] 1.27; P = .16) with only older age (aHR 1.08; P < .0001) and  history of VTE (aHR 31.63; P < .0001) remaining associated with an increased risk for VTE after multivariate adjustment.

Study details: This retrospective cohort study included 5,275 patients with newly diagnosed PsA who were matched with 21,011 control individuals without PsA.

Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.

Source: Gazitt T et al. Arthritis Res Ther. 2022;24:16 (Jan 7). Doi: 10.1186/s13075-021-02703-8.

Key clinical point: Increased risk for venous thromboembolism (VTE) in patients with psoriatic arthritis (PsA) seemed to be associated with underlying comorbidities and not independently associated with PsA.

Major finding: During follow-up, 1.2% vs. 0.8% patients in the PsA vs. control group were diagnosed with VTE, but this association was not statistically significant after adjusting for demographic factors and comorbidities (adjusted hazard ratio [aHR] 1.27; P = .16) with only older age (aHR 1.08; P < .0001) and  history of VTE (aHR 31.63; P < .0001) remaining associated with an increased risk for VTE after multivariate adjustment.

Study details: This retrospective cohort study included 5,275 patients with newly diagnosed PsA who were matched with 21,011 control individuals without PsA.

Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.

Source: Gazitt T et al. Arthritis Res Ther. 2022;24:16 (Jan 7). Doi: 10.1186/s13075-021-02703-8.

Key clinical point: Increased risk for venous thromboembolism (VTE) in patients with psoriatic arthritis (PsA) seemed to be associated with underlying comorbidities and not independently associated with PsA.

Major finding: During follow-up, 1.2% vs. 0.8% patients in the PsA vs. control group were diagnosed with VTE, but this association was not statistically significant after adjusting for demographic factors and comorbidities (adjusted hazard ratio [aHR] 1.27; P = .16) with only older age (aHR 1.08; P < .0001) and  history of VTE (aHR 31.63; P < .0001) remaining associated with an increased risk for VTE after multivariate adjustment.

Study details: This retrospective cohort study included 5,275 patients with newly diagnosed PsA who were matched with 21,011 control individuals without PsA.

Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.

Source: Gazitt T et al. Arthritis Res Ther. 2022;24:16 (Jan 7). Doi: 10.1186/s13075-021-02703-8.

Key clinical point: Patients with juvenile psoriatic arthritis (JPsA) were more likely to develop uveitis if they were diagnosed with PsA at a younger age or were antinuclear antibody (ANA) positive, with higher disease activity being the only factor significantly associated with the presence of uveitis.

Major finding: Patients with JPsA with vs. without uveitis were younger at JPsA onset (5.3 years vs. 9.3 years) and were more frequently positive for ANA (60.3% vs. 37%; both P < .001). The mean clinical Juvenile Arthritis Disease Activity Score 10 was the only factor significantly associated with the development of uveitis in patients with JPsA (hazard ratio 1.16; P = .025).

Study details: This was an analysis of cross-sectional data from 1,862 patients with JPsA from the National Pediatric Rheumatological Database. Of the patients in the study, 122 developed uveitis.

Disclosures: This study was funded by the Federal Ministry for Research and Education, Deutsche Kinderrheuma-Stiftung, and others. Some of the authors declared receiving honoraria and research grants from several sources.

Source: Walscheid K et al. J Rheumatol. 2022 (Jan 15). Doi: 10.3899/jrheum.210755.

Key clinical point: Patients with juvenile psoriatic arthritis (JPsA) were more likely to develop uveitis if they were diagnosed with PsA at a younger age or were antinuclear antibody (ANA) positive, with higher disease activity being the only factor significantly associated with the presence of uveitis.

Major finding: Patients with JPsA with vs. without uveitis were younger at JPsA onset (5.3 years vs. 9.3 years) and were more frequently positive for ANA (60.3% vs. 37%; both P < .001). The mean clinical Juvenile Arthritis Disease Activity Score 10 was the only factor significantly associated with the development of uveitis in patients with JPsA (hazard ratio 1.16; P = .025).

Study details: This was an analysis of cross-sectional data from 1,862 patients with JPsA from the National Pediatric Rheumatological Database. Of the patients in the study, 122 developed uveitis.

Disclosures: This study was funded by the Federal Ministry for Research and Education, Deutsche Kinderrheuma-Stiftung, and others. Some of the authors declared receiving honoraria and research grants from several sources.

Source: Walscheid K et al. J Rheumatol. 2022 (Jan 15). Doi: 10.3899/jrheum.210755.

Key clinical point: Patients with juvenile psoriatic arthritis (JPsA) were more likely to develop uveitis if they were diagnosed with PsA at a younger age or were antinuclear antibody (ANA) positive, with higher disease activity being the only factor significantly associated with the presence of uveitis.

Major finding: Patients with JPsA with vs. without uveitis were younger at JPsA onset (5.3 years vs. 9.3 years) and were more frequently positive for ANA (60.3% vs. 37%; both P < .001). The mean clinical Juvenile Arthritis Disease Activity Score 10 was the only factor significantly associated with the development of uveitis in patients with JPsA (hazard ratio 1.16; P = .025).

Study details: This was an analysis of cross-sectional data from 1,862 patients with JPsA from the National Pediatric Rheumatological Database. Of the patients in the study, 122 developed uveitis.

Disclosures: This study was funded by the Federal Ministry for Research and Education, Deutsche Kinderrheuma-Stiftung, and others. Some of the authors declared receiving honoraria and research grants from several sources.

Source: Walscheid K et al. J Rheumatol. 2022 (Jan 15). Doi: 10.3899/jrheum.210755.

Key clinical point: Patients with psoriasis and concomitant psoriatic arthritis (PsA) were at greater risk of developing endometriosis.

Major finding: A history of psoriasis with concomitant PsA was associated with an increased risk for subsequent endometriosis diagnosis (hazard ratio [HR] 2.01; 95% CI 1.23-3.30), which persisted even after adjusting for comorbidities such as hypertension, hypercholesterolemia, and cardiovascular disease (HR 1.94; 95% CI 1.18-3.18).

Study details: Findings are from an analysis of 4,112 patients with laparoscopically confirmed endometriosis and 767 patients with psoriasis, of which 140 had concomitant PsA from the Nurses’ Health Study II.

Disclosures: This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. The authors reported no conflicts of interest.

Source: Harris HR et al. Am J Epidemiol. 2022 (Jan 13). Doi: 10.1093/aje/kwac009.

Key clinical point: Patients with psoriasis and concomitant psoriatic arthritis (PsA) were at greater risk of developing endometriosis.

Major finding: A history of psoriasis with concomitant PsA was associated with an increased risk for subsequent endometriosis diagnosis (hazard ratio [HR] 2.01; 95% CI 1.23-3.30), which persisted even after adjusting for comorbidities such as hypertension, hypercholesterolemia, and cardiovascular disease (HR 1.94; 95% CI 1.18-3.18).

Study details: Findings are from an analysis of 4,112 patients with laparoscopically confirmed endometriosis and 767 patients with psoriasis, of which 140 had concomitant PsA from the Nurses’ Health Study II.

Disclosures: This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. The authors reported no conflicts of interest.

Source: Harris HR et al. Am J Epidemiol. 2022 (Jan 13). Doi: 10.1093/aje/kwac009.

Key clinical point: Patients with psoriasis and concomitant psoriatic arthritis (PsA) were at greater risk of developing endometriosis.

Major finding: A history of psoriasis with concomitant PsA was associated with an increased risk for subsequent endometriosis diagnosis (hazard ratio [HR] 2.01; 95% CI 1.23-3.30), which persisted even after adjusting for comorbidities such as hypertension, hypercholesterolemia, and cardiovascular disease (HR 1.94; 95% CI 1.18-3.18).

Study details: Findings are from an analysis of 4,112 patients with laparoscopically confirmed endometriosis and 767 patients with psoriasis, of which 140 had concomitant PsA from the Nurses’ Health Study II.

Disclosures: This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. The authors reported no conflicts of interest.

Source: Harris HR et al. Am J Epidemiol. 2022 (Jan 13). Doi: 10.1093/aje/kwac009.

Key clinical point: Secukinumab showed early and clinically meaningful improvements in patient-reported outcomes (PRO) in adults with psoriatic arthritis (PsA).

Major finding: At week 16, patients in all secukinumab treatment groups vs. placebo showed significant improvement in all PRO (P ≤ .0001) except for the 36-item Short-Form Health Survey mental component summary. Patients receiving 300 mg secukinumab showed significant and clinically meaningful improvements as early as week 1 (P < .05).

Study details: Findings are from the phase 3 FUTURE 5 trial including 996 adults with active PsA who were randomly assigned to 300 mg secukinumab, 150 mg secukinumab  (with/without loading dose), or placebo.

Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants or consulting and speaker’s bureau fees from various sources including Novartis. Four authors declared being past/current employees or shareholders of Novartis.

Source: Strand V et al. Lancet Rheumatol. 2022 (Feb 1). Doi: 10.1016/S2665-9913(21)00354-4.

Key clinical point: Secukinumab showed early and clinically meaningful improvements in patient-reported outcomes (PRO) in adults with psoriatic arthritis (PsA).

Major finding: At week 16, patients in all secukinumab treatment groups vs. placebo showed significant improvement in all PRO (P ≤ .0001) except for the 36-item Short-Form Health Survey mental component summary. Patients receiving 300 mg secukinumab showed significant and clinically meaningful improvements as early as week 1 (P < .05).

Study details: Findings are from the phase 3 FUTURE 5 trial including 996 adults with active PsA who were randomly assigned to 300 mg secukinumab, 150 mg secukinumab  (with/without loading dose), or placebo.

Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants or consulting and speaker’s bureau fees from various sources including Novartis. Four authors declared being past/current employees or shareholders of Novartis.

Source: Strand V et al. Lancet Rheumatol. 2022 (Feb 1). Doi: 10.1016/S2665-9913(21)00354-4.

Key clinical point: Secukinumab showed early and clinically meaningful improvements in patient-reported outcomes (PRO) in adults with psoriatic arthritis (PsA).

Major finding: At week 16, patients in all secukinumab treatment groups vs. placebo showed significant improvement in all PRO (P ≤ .0001) except for the 36-item Short-Form Health Survey mental component summary. Patients receiving 300 mg secukinumab showed significant and clinically meaningful improvements as early as week 1 (P < .05).

Study details: Findings are from the phase 3 FUTURE 5 trial including 996 adults with active PsA who were randomly assigned to 300 mg secukinumab, 150 mg secukinumab  (with/without loading dose), or placebo.

Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants or consulting and speaker’s bureau fees from various sources including Novartis. Four authors declared being past/current employees or shareholders of Novartis.

Source: Strand V et al. Lancet Rheumatol. 2022 (Feb 1). Doi: 10.1016/S2665-9913(21)00354-4.

Key clinical point: The risk for all-cause and atopic dermatitis (AD)-related hospitalization was significantly lower in adult patients with moderate-to-severe AD who received dupilumab vs. placebo.

Major finding: Risk for all-cause hospitalizations was lower by 62% (risk ratio [RR] 0.38; P < .001) and AD-related hospitalizations by 79% (RR 0.21; P < .001) in patients who received dupilumab vs. placebo.

Study details: Findings are from a post hoc analysis of pooled data from 7 phase 2/3 trials including 2,932 patients with moderate-to-severe AD who were randomly assigned to 300 mg dupilumab (every 2 weeks or weekly) with or without topical corticosteroids or placebo for 12, 16, or 52 weeks.

Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants or receiving grants and honoraria from several sources. Six authors declared being employees or shareholders of Sanofi or Regeneron or Sanofi Genzyme.

Source: Silverberg JI et al. J Allergy Clin Immunol Pract. 2022 (Jan 12). Doi:  10.1016/j.jaip.2021.11.034.

Key clinical point: The risk for all-cause and atopic dermatitis (AD)-related hospitalization was significantly lower in adult patients with moderate-to-severe AD who received dupilumab vs. placebo.

Major finding: Risk for all-cause hospitalizations was lower by 62% (risk ratio [RR] 0.38; P < .001) and AD-related hospitalizations by 79% (RR 0.21; P < .001) in patients who received dupilumab vs. placebo.

Study details: Findings are from a post hoc analysis of pooled data from 7 phase 2/3 trials including 2,932 patients with moderate-to-severe AD who were randomly assigned to 300 mg dupilumab (every 2 weeks or weekly) with or without topical corticosteroids or placebo for 12, 16, or 52 weeks.

Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants or receiving grants and honoraria from several sources. Six authors declared being employees or shareholders of Sanofi or Regeneron or Sanofi Genzyme.

Source: Silverberg JI et al. J Allergy Clin Immunol Pract. 2022 (Jan 12). Doi:  10.1016/j.jaip.2021.11.034.

Key clinical point: The risk for all-cause and atopic dermatitis (AD)-related hospitalization was significantly lower in adult patients with moderate-to-severe AD who received dupilumab vs. placebo.

Major finding: Risk for all-cause hospitalizations was lower by 62% (risk ratio [RR] 0.38; P < .001) and AD-related hospitalizations by 79% (RR 0.21; P < .001) in patients who received dupilumab vs. placebo.

Study details: Findings are from a post hoc analysis of pooled data from 7 phase 2/3 trials including 2,932 patients with moderate-to-severe AD who were randomly assigned to 300 mg dupilumab (every 2 weeks or weekly) with or without topical corticosteroids or placebo for 12, 16, or 52 weeks.

Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants or receiving grants and honoraria from several sources. Six authors declared being employees or shareholders of Sanofi or Regeneron or Sanofi Genzyme.

Source: Silverberg JI et al. J Allergy Clin Immunol Pract. 2022 (Jan 12). Doi:  10.1016/j.jaip.2021.11.034.

Key clinical point: Under real-world settings, dupilumab was an effective and safe therapeutic option for adolescents and adults with moderate-to-severe atopic dermatitis (AD).

Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 53.3% and 79.4% of patients at weeks 12 and 48, respectively. Overall, mild adverse events were reported by 32% of patients, with the most frequent being conjunctivitis, persistent facial erythema, and arthritis/arthralgia.

Study details: Findings are from a nationwide, retrospective 48-week study including 169 patients aged 12 years or older with moderate-to-severe AD who received dupilumab.

Disclosures: This study did not report any source of funding. Some authors declared serving as a speakers and principal investigators or receiving consulting fees, research grants, and honoraria from several sources.

Source: Torres T et al. J Dermatolog Treat. 2022 (Jan 31). Doi: 10.1080/09546634.2022.2035309

Key clinical point: Under real-world settings, dupilumab was an effective and safe therapeutic option for adolescents and adults with moderate-to-severe atopic dermatitis (AD).

Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 53.3% and 79.4% of patients at weeks 12 and 48, respectively. Overall, mild adverse events were reported by 32% of patients, with the most frequent being conjunctivitis, persistent facial erythema, and arthritis/arthralgia.

Study details: Findings are from a nationwide, retrospective 48-week study including 169 patients aged 12 years or older with moderate-to-severe AD who received dupilumab.

Disclosures: This study did not report any source of funding. Some authors declared serving as a speakers and principal investigators or receiving consulting fees, research grants, and honoraria from several sources.

Source: Torres T et al. J Dermatolog Treat. 2022 (Jan 31). Doi: 10.1080/09546634.2022.2035309

Key clinical point: Under real-world settings, dupilumab was an effective and safe therapeutic option for adolescents and adults with moderate-to-severe atopic dermatitis (AD).

Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 53.3% and 79.4% of patients at weeks 12 and 48, respectively. Overall, mild adverse events were reported by 32% of patients, with the most frequent being conjunctivitis, persistent facial erythema, and arthritis/arthralgia.

Study details: Findings are from a nationwide, retrospective 48-week study including 169 patients aged 12 years or older with moderate-to-severe AD who received dupilumab.

Disclosures: This study did not report any source of funding. Some authors declared serving as a speakers and principal investigators or receiving consulting fees, research grants, and honoraria from several sources.

Source: Torres T et al. J Dermatolog Treat. 2022 (Jan 31). Doi: 10.1080/09546634.2022.2035309

Key clinical point: The risk for overall infection was not higher in children and adolescents with moderate-to-severe or severe atopic dermatitis (AD) treated with dupilumab vs. placebo; however, the risk for skin infections was significantly lower with dupilumab.

Major finding: Dupilumab did not increase the risk for overall infections (risk ratio [RR] 0.76; P = .051) and was associated with a reduced risk for total skin infections (RR 0.45; P = .003) compared with placebo.

Study details: This was a pooled analysis of 2 phase 3 trials including 612 adolescents or children with moderate-to-severe/severe AD who received dupilumab either as monotherapy (LIBERTY AD ADOL) or with concomitant topical corticosteroids (LIBERTY AD PEDS).

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as investigators, speakers, consultants, and scientific advisors or clinical study investigators, and advisory board members or receiving honoraria and grants from several sources. Six authors declared being employees or shareholders of Sanofi and Regeneron Pharmaceuticals.

Source: Paller AS et al. Pediatr Dermatol. 2022 (Jan 26). Doi: 10.1111/pde.14909

Key clinical point: The risk for overall infection was not higher in children and adolescents with moderate-to-severe or severe atopic dermatitis (AD) treated with dupilumab vs. placebo; however, the risk for skin infections was significantly lower with dupilumab.

Major finding: Dupilumab did not increase the risk for overall infections (risk ratio [RR] 0.76; P = .051) and was associated with a reduced risk for total skin infections (RR 0.45; P = .003) compared with placebo.

Study details: This was a pooled analysis of 2 phase 3 trials including 612 adolescents or children with moderate-to-severe/severe AD who received dupilumab either as monotherapy (LIBERTY AD ADOL) or with concomitant topical corticosteroids (LIBERTY AD PEDS).

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as investigators, speakers, consultants, and scientific advisors or clinical study investigators, and advisory board members or receiving honoraria and grants from several sources. Six authors declared being employees or shareholders of Sanofi and Regeneron Pharmaceuticals.

Source: Paller AS et al. Pediatr Dermatol. 2022 (Jan 26). Doi: 10.1111/pde.14909

Key clinical point: The risk for overall infection was not higher in children and adolescents with moderate-to-severe or severe atopic dermatitis (AD) treated with dupilumab vs. placebo; however, the risk for skin infections was significantly lower with dupilumab.

Major finding: Dupilumab did not increase the risk for overall infections (risk ratio [RR] 0.76; P = .051) and was associated with a reduced risk for total skin infections (RR 0.45; P = .003) compared with placebo.

Study details: This was a pooled analysis of 2 phase 3 trials including 612 adolescents or children with moderate-to-severe/severe AD who received dupilumab either as monotherapy (LIBERTY AD ADOL) or with concomitant topical corticosteroids (LIBERTY AD PEDS).

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as investigators, speakers, consultants, and scientific advisors or clinical study investigators, and advisory board members or receiving honoraria and grants from several sources. Six authors declared being employees or shareholders of Sanofi and Regeneron Pharmaceuticals.

Source: Paller AS et al. Pediatr Dermatol. 2022 (Jan 26). Doi: 10.1111/pde.14909